Fig. 6. Everolimus and plicamycin exhibit anticancer effects against CMS4 tumors.

A, B Schematic overview of the treatment schedule of LoVo or MDST8 tumors with everolimus (EVE) and plicamycin (PLI) in vivo. C–H Five million human colon cancer MDST8 or LoVo cells were injected subcutaneously (s.c.) into the flank of athymic immunodeficient nu/nu mice. When tumors became palpable, mice received a systemic intraperitoneal injection of EVE or PLI. n ≥ 6 mice per group. Results (means ± SD tumor growth curves) are plotted (*P < 0.05, ***P < 0.001). Overall survival is depicted, and P values (***P < 0.001) were calculated with a Log‐rank test (E, F). After EVE/PLI treatment, mice bearing MDST8 tumors were divided into three different groups, and tumor growth was monitored upon continuation or discontinuation of the treatment as indicated (G, H).